Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 4
1986 1
1987 7
1988 8
1989 3
1990 3
1991 3
1992 4
1993 3
1994 3
1995 1
1996 1
1997 3
1999 1
2000 3
2001 1
2002 2
2003 2
2004 1
2005 4
2006 1
2007 9
2008 3
2009 4
2010 5
2011 6
2012 3
2013 4
2014 10
2015 3
2016 2
2017 1
2018 4
2019 2
2020 2
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 19330334

119 results

Results by year

Filters applied: . Clear all
Page 1
Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
Lopes LF, Macedo CR, Aguiar Sdos S, Barreto JH, Martins GE, Sonaglio V, Milone M, Lima ER, Almeida MT, Lopes PM, Watanabe FM, D'Andrea ML, Pianovski MA, Melaragno R, Vianna SM, Moreira ME, Bruniera P, de Oliveira CZ. Lopes LF, et al. J Clin Oncol. 2016 Feb 20;34(6):603-10. doi: 10.1200/JCO.2014.59.1420. Epub 2016 Jan 4. J Clin Oncol. 2016. PMID: 26729441
Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group. Hartmann JT, et al. J Clin Oncol. 2007 Dec 20;25(36):5742-7. doi: 10.1200/JCO.2007.11.9099. J Clin Oncol. 2007. PMID: 18089869 Clinical Trial.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Fizazi K, et al. Lancet Oncol. 2014 Dec;15(13):1442-1450. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13. Lancet Oncol. 2014. PMID: 25456363 Free PMC article. Clinical Trial.
Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S, et al. J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461. J Clin Oncol. 2008. PMID: 18202419 Clinical Trial.
119 results